New Data Reinforces Potential Of Sanofi's Sutimlimab After Shock FDA Snub
Second Positive Phase III Trial In Cold Agglutinin Disease
Having suffered a setback last year when deficiencies at a third-party manufacturer scuppered hopes of a quick US approval of sutimlimab for cold agglutinin disease, Sanofi has released more promising data on its C1s inhibitor at the European Hematology Association meeting.
You may also be interested in...
The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.